October 22, 2025Modern Rheumatology

Effectiveness and safety of tocilizumab, an anti–interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational study

View Full Paper

Ask AI

Bookmark

Authors

NNNorihiro NishimotoOsaka Nishi Clinic MMMiho MurakamiOsaka City University TJTakeshi JohkohKansai Rosai Hospital

Discussion

Member takes

Implication

Observational study found tocilizumab improved symptoms in 342 patients with multicentric Castleman disease, indicating it is a safe treatment option.

Key Points

Treatment with tocilizumab led to significant lymph node regression in 58.9% of patients with multicentric Castleman disease.
A total of 342 Japanese patients were treated with an intravenous infusion of tocilizumab every 2 weeks for up to 3 years.
Adverse events included infections and respiratory disorders, but no new safety concerns were reported.
Results suggest that tocilizumab effectively reduces corticosteroid use while managing lymphoproliferative disorder symptoms.

Cite This Study

Nishimoto et al. (2025) studied this question.

synapsesocial.com/papers/68f8a381c0c01e5ef8abdb2e https://doi.org/10.1093/mr/roaf100

View Full Paper

Ask AI

Bookmark

Implication

Observational study found tocilizumab improved symptoms in 342 patients with multicentric Castleman disease, indicating it is a safe treatment option.

Effectiveness and safety of tocilizumab, an anti–interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational study

Discussion

Member takes

Implication

Key Points

Cite This Study

Effectiveness and safety of tocilizumab, an anti–interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider